Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

Lignende værker

• Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
  af: Lumry, William R., et al.
  Udgivet: (2021)
• Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
  af: Li, H. Henry, et al.
  Udgivet: (2019)
• Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
  af: H. Henry Li, et al.
  Udgivet: (2019-08-01)
• Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
  af: Busse, Paula J., et al.
  Udgivet: (2018)
• Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
  af: Riedl, Marc A., et al.
  Udgivet: (2020)